Mélanie Saint-Jean

Learn More
BACKGROUND Ulcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel treatment for IH. OBJECTIVE To evaluate our experience of propranolol in the management of ulcerated IH. METHODS A national, multicenter, retrospective, observational study was conducted. Data were(More)
37 children presenting with West's syndrome were studied by computerized tomography scanning. An abnormality consisting of diffuse cerebral atrophy, predominating in the fronto-temporal region, was demonstrated in 30 cases. The abnormality was sometimes associated with calcification (tuberous sclerosis) or malformation (agenesis of the corpus callosum). The(More)
Rituximab is an anti-CD20 monoclonal antibody increasingly used in haematology and rheumatology, but also in internal medicine and dermatology. It has a good tolerance profile without known increased risk of cancer. We report a case of nodular melanoma with a 4.8 mm Breslow thickness that appeared after 2 years of rituximab in a 45-year-old patient with(More)
BACKGROUND Vemurafenib is a BRAF inhibitor indicated for the treatment of metastatic melanoma. We report the two first cases of severe and prolonged radiotherapy-induced visceral toxicity in patients treated concomitantly with vemurafenib: a brain radionecrosis and an anorectitis. It raises the question of both the risks of this association and its benefit(More)
Les syndromes paranéoplasiques sont des manifestations systémiques diverses évoluant en parallèle d’une néoplasie solide ou d’une hémopathie maligne. L’association d’une maladie de Hodgkin (MH) à des syndromes paranéoplasiques est classiquement rapportée dans la littérature, à type de manifestations cutanées (ichtyose acquise, pemphigus. . .), neurologiques(More)
UNLABELLED There is increasing evidence that melanoma cells express TLR2, -3, and -4. However, the expression of other TLRs by these cells still remains unknown. We investigated the expression patterns of TLR2, -3, -4, -7, -8 and -9 both on melanoma-invaded lymph nodes and on melanoma cell lines. TLR2, -3, -4, -7 and -9 mRNA expression was determined by(More)